🔎 Trials Near Me

홈 › 버킷 림프종 › 워싱턴

워싱턴의 버킷 림프종 임상 시험

버킷 림프종 관련 연구 12개가 워싱턴 내 여러 지역에서 참여자를 모집하고 있습니다.

워싱턴의 도시

공식 연구 텍스트(영어)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
  • Mary Bridge Children's Hospital and Health Center, Tacoma
피험자 모집 중2상
366 Days – 46 Years · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
피험자 모집 중2상
365 Days · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Fred Hutchinson Cancer Research Center, Seattle
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT07648264

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Medical Center-First Hill, Seattle
피험자 모집 중3상
18세 ~ 39세 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT03150693

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
  • Mary Bridge Children's Hospital and Health Center, Tacoma
  • 외 1개
피험자 모집 중2상
1세 ~ 30세 · 모든 성별 · 2026. 9. 1. 업데이트됨 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
  • Mary Bridge Children's Hospital and Health Center, Tacoma
피험자 모집 중3상
365 Days – 25 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT03959085

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
피험자 모집 중2상건강한 지원자 환영
6 Months · 모든 성별 · 2026. 5. 29. 업데이트됨 · NCT04195633

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 23. 업데이트됨 · NCT07097363

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Fred Hutchinson Cancer Center, Seattle
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 2. 13. 업데이트됨 · NCT05544019

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • Fred Hutchinson Cancer Research Center, Seattle
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 11. 5. 업데이트됨 · NCT04260022

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

  • Fred Hutchinson Cancer Center, Seattle
피험자 모집 중1상
18세 이상 · 모든 성별 · 2024. 11. 15. 업데이트됨 · NCT06034275

ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.